NOX4 mediates activation of FoxO3a and matrix metalloproteinase-2 expression by urotensin-II

Molecular Biology of the Cell

Volumn 22, Issue 22, 2011, Pages 4424-4434

  Diebold, Isabel ^a   Petry, Andreas ^a   Burger, Maximilian ^a   Hess, John ^a   Gor̈lach, Agnes ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Munich Heart Alliance   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN 14 3 3; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TRANSCRIPTION FACTOR FKHRL1; UROTENSIN II;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SMOOTH MUSCLE FIBER; UPREGULATION;

14-3-3 PROTEINS; ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MATRIX METALLOPROTEINASE 2; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NADPH OXIDASE; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; UROTENSINS;

MUS;

EID: 81755162123     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E10-12-0971     Document Type: Article

References (51)

1. Abid MR, Yano K, Guo S, Patel VI, Shrikhande G, Spokes KC, Ferran C, Aird WC (2005). Forkhead transcription factors inhibit vascular smooth muscle cell proliferation and neointimal hyperplasia. J Biol Chem 280, 29864-29873. (Pubitemid 41177064)
2. Accili D, Arden KC (2004). FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117, 421-426. (Pubitemid 38610228)
3. Back M, Ketelhuth DF, Agewall S (2010). Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 52, 410-428.
4. Bonello S, Zahringer C, BelAiba RS, Djordjevic T, Hess J, Michiels C, Kietzmann T, Gorlach A (2007). Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol 27, 755-761. (Pubitemid 46606703)
5. Brunet A et al. (2004). Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303, 2011-2015. (Pubitemid 38393275)
6. Calnan DR, Brunet A (2008). The FoxO code. Oncogene 27, 2276-2288. (Pubitemid 351501779)
7. Castrillon DH, Miao L, Kollipara R, Horner JW, DePinho RA (2003). Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science 301, 215-218. (Pubitemid 36858475)
8. Chai SB, Li XM, Pang YZ, Qi YF, Tang CS (2010). Increased plasma levels of endothelin-1 and urotensin-II in patients with coronary heart disease. Heart Vessels 25, 138-143.
9. Czymai T, Viemann D, Sticht C, Molema G, Goebeler M, Schmidt M (2010). FOXO3 modulates endothelial gene expression and function by classical and alternative mechanisms. J Biol Chem 285, 10163-10178.
10. Diebold I, Petry A, Hess J, Gorlach A (2010). The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1. Mol Biol Cell 21, 2087-2096.
11. Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, Gorlach A (2005). Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 25, 519-525.
12. Djordjevic T, Gorlach A (2007). Urotensin-II in the lung: a matter for vascular remodelling and pulmonary hypertension? Thromb Haemost 98, 952-962. (Pubitemid 350091122)
13. Djordjevic T, Hess J, Herkert O, Gorlach A, BelAiba RS (2004). Rac regulates thrombin-induced tissue factor expression in pulmonary artery smooth muscle cells involving the nuclear factor-kappaB pathway. Antioxid Redox Signal 6, 713-720. (Pubitemid 38890788)
14. Essers MA, Weijzen S, de Vries-Smits AM, Saarloos I, de Ruiter ND, Bos JL, Burgering BM (2004). FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J 23, 4802-4812. (Pubitemid 40069710)
15. Frescas D, Valenti L, Accili D (2005). Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem 280, 20589-20595. (Pubitemid 40776761)
16. Furuyama T, Nakazawa T, Nakano I, Mori N (2000). Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochem J 349, 629-634. (Pubitemid 30465799)
17. Grote K, Flach I, Luchtefeld M, Akin E, Holland SM, Drexler H, Schieffer B (2003). Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res 92, e80-e86.
18. Hassoun PM (2005). Deciphering the "matrix" in pulmonary vascular remodelling. Eur Respir J 25, 778-779.
19. Hirakawa Y, Gericke M, Cohen RA, Bolotina VM (1999). Ca(2+)-dependent Cl(-) channels in mouse and rabbit aortic smooth muscle cells: regulation by intracellular Ca(2+) and NO. Am J Physiol 277, H1732-H1744.
20. Huang H, Tindall DJ (2007). Dynamic FoxO transcription factors. J Cell Sci 120, 2479-2487. (Pubitemid 47323857)
21. Lee HY et al. (2007). Forkhead transcription factor FOXO3a is a negative regulator of angiogenic immediate early gene CYR61, leading to inhibition of vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 100, 372-380.
22. Lee HY et al. (2008). Forkhead factor, FOXO3a, induces apoptosis of endothelial cells through activation of matrix metalloproteinases. Arterioscler Thromb Vasc Biol 28, 302-308.
23. Lepetit H, Eddahibi S, Fadel E, Frisdal E, Munaut C, Noel A, Humbert M, Adnot S, D'Ortho MP, Lafuma C (2005). Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J 25, 834-842. (Pubitemid 40667681)
24. Li G, Lee YF, Liu S, Cai Y, Xie S, Liu NC, Bao BY, Chen Z, Chang C (2008). Oxidative stress stimulates testicular orphan receptor 4 through forkhead transcription factor forkhead box O3a. Endocrinology 149, 3490-3499. (Pubitemid 351919587)
25. Li H, Liang J, Castrillon DH, DePinho RA, Olson EN, Liu ZP (2007). FoxO4 regulates tumor necrosis factor alpha-directed smooth muscle cell migration by activating matrix metalloproteinase 9 gene transcription. Mol Cell Biol 27, 2676-2686. (Pubitemid 46581357)
26. Liu ZP, Wang Z, Yanagisawa H, Olson EN (2005). Phenotypic modulation of smooth muscle cells through interaction of Foxo4 and myocardin. Dev Cell 9, 261-270. (Pubitemid 41051744)
27. Maguire JJ, Davenport AP (2002). Is urotensin-II the new endothelin? Br J Pharmacol 137, 579-588. (Pubitemid 35333083)
28. Maiese K, Chong ZZ, Shang YC, Hou J (2009). FoxO proteins: cunning concepts and considerations for the cardiovascular system. Clin Sci (Lond) 116, 191-203.
29. McCawley LJ, Matrisian LM (2001). Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 13, 534-540. (Pubitemid 32817010)
30. Meng D, Lv DD, Fang J (2008). Insulin-like growth factor-I induces reactive oxygen species production and cell migration through Nox4 and Rac1 in vascular smooth muscle cells. Cardiovasc Res 80, 299-308.
31. Monsalve M, Olmos Y (2011). The complex biology of FOXO. Curr Drug Targets 12,1322-1350.
32. Obsil T, Obsilova V (2011). Structural basis for DNA recognition by FOXO proteins. Biochim Biophys Acta 1813,1946-1953.
33. Ono H, Ichiki T, Ohtsubo H, Fukuyama K, Imayama I, Hashiguchi Y, Sadoshima J, Sunagawa K (2005). Critical role of Mst1 in vascular remodeling after injury. Arterioscler Thromb Vasc Biol 25, 1871-1876. (Pubitemid 41243456)
34. Papadopoulos P, Bousette N, Giaid A (2008). Urotensin-II and cardiovascular remodeling. Peptides 29, 764-769. (Pubitemid 351522368)
35. Petry A, Djordjevic T, Weitnauer M, Kietzmann T, Hess J, Gorlach A (2006). NOX2 and NOX4 mediate proliferative response in endothelial cells. Antioxid Redox Signal 8, 1473-1484. (Pubitemid 44726324)
36. Potente M, Urbich C, Sasaki K, Hofmann WK, Heeschen C, Aicher A, Kollipara R, DePinho RA, Zeiher AM, Dimmeler S (2005). Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest 115, 2382-2392. (Pubitemid 41266200)
37. Raffetto JD, Khalil RA (2008). Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 75, 346-359. (Pubitemid 350298459)
38. Rauch BH, Bretschneider E, Braun M, Schror K (2002). Factor Xa releases matrix metalloproteinase-2 (MMP-2) from human vascular smooth muscle cells and stimulates the conversion of pro-MMP-2 to MMP-2: role of MMP-2 in factor Xa-induced DNA synthesis and matrix invasion. Circ Res 90, 1122-1127. (Pubitemid 34627912)
39. Ray JL, Leach R, Herbert JM, Benson M (2001). Isolation of vascular smooth muscle cells from a single murine aorta. Methods Cell Sci 23, 185-188. (Pubitemid 34863290)
40. Ross B, McKendy K, Giaid A (2010). Role of urotensin II in health and disease. Am J Physiol Regul Integr Comp Physiol 298, R1156-R1172.
41. Sauzeau V, Le Mellionnec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G (2001). Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88, 1102-1104. (Pubitemid 34132508)
42. Shang YC, Chong ZZ, Hou J, Maiese K (2009). FoxO3a governs early microglial proliferation and employs mitochondrial depolarization with caspase 3, 8, and 9 cleavage during oxidant induced apoptosis. Curr Neurovasc Res 6, 223-238.
43. Simpson CM, Penny DJ, Stocker CF, Shekerdemian LS (2006). Urotensin II is raised in children with congenital heart disease. Heart 92, 983-984. (Pubitemid 43974071)
44. Storz P (2011). Forkhead homeobox type O transcription factors in the responses to oxidative stress. Antioxid Redox Signal 14, 593-605.
45. Storz P, Doppler H, Copland JA, Simpson KJ, Toker A (2009). FOXO3a promotes tumor cell invasion through the induction of matrix metalloproteinases. Mol Cell Biol 29, 4906-4917.
46. Suguro T, Watanabe T, Kodate S, Xu G, Hirano T, Adachi M, Miyazaki A (2008). Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. Clin Sci (Lond) 115, 327-334.
47. Sunayama J, Tsuruta F, Masuyama N, Gotoh Y (2005). JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J Cell Biol 170, 295-304. (Pubitemid 41043811)
48. Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ, Jr, DiStefano PS, Chiang LW, Greenberg ME (2002). DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 296, 530-534. (Pubitemid 34408672)
49. Volcik KA, Campbell S, Chambless LE, Coresh J, Folsom AR, Mosley TH, Ni H, Wagenknecht LE, Wasserman BA, Boerwinkle E (2010). MMP2 genetic variation is associated with measures of fibrous cap thickness: The Atherosclerosis Risk in Communities Carotid MRI Study. Atherosclerosis 210, 188-193.
50. Wang H, Mehta JL, Chen K, Zhang X, Li D (2004). Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. J Cardiovasc Pharmacol 44, 577-581. (Pubitemid 39441698)
51. Xuan Z, Zhang MQ (2005). From worm to human: bioinformatics approaches to identify FOXO target genes. Mech Ageing Dev 126, 209-215. (Pubitemid 40021803)